Caladrius Biosciences, Inc.
("Caladrius") CLBS, a cell therapy leader with a Phase 3 clinical
program in immuno-oncology and a portfolio of projects in immune modulation
and regenerative medicine, announced today that it has received notice of an
award from the National Eye Institute of the National Institutes of Health
for a project to investigate 3D retinal constructs for vision restoration in
patients with age-related macular degeneration. The total planned amount for
the grant is $671,633. Of that total, $344,498 has been awarded for the 2015
budget period.
The grant supports a three-year study led by Dr. Hans S. Keirstead,
Caladrius' Senior Vice President, Research, and Chief Science Officer. Dr.
Keirstead's research team will further the development of Caladrius'
proprietary methods to generate 3D retinal constructs from human-induced
pluripotent stem cells, and test their ability to restore vision, using a
new model of rodent retinal degeneration.
"This grant builds on our April announcement of additional non-dilutive
funding to support discovery programs exploring application of our
technologies in the area of retinal regeneration. We thank the NIH and its
reviewers for their confidence in our discovery capabilities," said Dr.
David J. Mazzo, Chief Executive Officer of Caladrius.
Approximately 11 million people in the United States have some form of
age-related macular degeneration. This number is expected to double to
nearly 22 million by 2050. Estimates of the global cost of visual impairment
due to age-related macular degeneration are close to $343 billion, including
$255 billion in direct health care costs.
This research is supported by the National Eye Institute of the National
Institutes of Health under Award Number R01EY024045. The content of this
press release is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in